Mindie H Nguyen is Professor of Medicine, a Stanford Cancer Institute member and specializes in the treatment and prevention of primary liver cancer such as hepatocellular carcinoma (HCC). Dr. Nguyen is also a Professor of Epidemiology and Population Health by courtesy at Stanford. Dr. Nguyen has served as Director of the Hepatology Fellowship Program in the Division of Gastroenterology and Hepatology and the Liver Transplant Program. Currently, she is Director of the Hepatology Clerkship, a member of Stanford Bio-X, and Stanford Population Science, a member of the Appointments and Promotions Committee and a Diversity LENS Advocate for the Department of Medicine, assisting in the promotion of equity and diversity in the professoriate search process. Dr. Nguyen’s clinical and research focus includes patients with cirrhosis, viral hepatitis, nonalcoholic fatty liver disease (NAFLD/NASH). Her goal is to promote early detection of liver tumors and to prevent and treat complications from chronic liver diseases and liver cancer. She has extensive experience in performing clinical trials on liver cancer, fatty liver, cirrhosis, and viral hepatitis.
Mindie H Nguyen is Professor of Medicine, a Stanford Cancer Institute member and specializes in the treatment and prevention of primary liver cancer such as hepatocellular carcinoma (HCC). Dr. Nguyen is also a Professor of Epidemiology and Population Health by courtesy at Stanford. Dr. Nguyen has served as Director of the Hepatology Fellowship Program in the Division of Gastroenterology and Hepatology and the Liver Transplant Program. Currently, she is Director of the Hepatology Clerkship, a member of Stanford Bio-X, and Stanford Population Science, a member of the Appointments and Promotions Committee and a Diversity LENS Advocate for the Department of Medicine, assisting in the promotion of equity and diversity in the professoriate search process. Dr. Nguyen’s clinical and research focus includes patients with cirrhosis, viral hepatitis, nonalcoholic fatty liver disease (NAFLD/NASH). Her goal is to promote early detection of liver tumors and to prevent and treat complications from chronic liver diseases and liver cancer. She has extensive experience in performing clinical trials on liver cancer, fatty liver, cirrhosis, and viral hepatitis.